Source: International Congress 2016 – Orphan diseases I
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ilaria Campo (Pavia, Italy), Francesca Mariani, Ilaria Campo, Elena Paracchini, Davide Piloni, Zamir Kadija, Michele Zorzetto, Annalisa De Silvestri, Carmine Tinelli, Federica Meloni, Maurizio Luisetti. Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL). Eur Respir J 2016; 48: Suppl. 60, 3876

Member's Comments

No comment yet.

Related content which might interest you: Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume? Source: International Congress 2015 – IIPs: orphan Year: 2015 Whole lung lavage therapy (WLL) of pulmonary alveolar proteinosis (PAP): A global survey of current practices and procedures Source: International Congress 2016 – Orphan diseases I Year: 2016 Is it possible to predict the outcome of the whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP)? Source: International Congress 2015 – IIPs: orphan Year: 2015 Early effect of whole lung lavage (WLL) on surfactant homeostasis in pulmonary alveolar proteinosis (PAP) Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Pulmonary alveolar proteinosis (PAP) in exogenous toxic alveolitis (ETA) patients Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015 Serum biomarkers as prognostic factors of autoimmune pulmonary alveolar proteinosis after whole lung lavage Source: International Congress 2016 – Orphan diseases I Year: 2016 Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis Source: Eur Respir J 2004; 24: Suppl. 48, 670s Year: 2004 Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child Source: Eur Respir J 2003; 22: Suppl. 45, 309s Year: 2003 Whole lung lavage (WLL) in pulmonary alveolar proteinosis (PAP): long-term lung function follow-up Source: Eur Respir J 2001; 18: Suppl. 33, 220s Year: 2001 Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP) Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF Source: Eur Respir J 2002; 20: Suppl. 38, 447s Year: 2002 High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Lung function and symptom improvement in patients with pulmonary alveolar proteinosis after whole lung lavage or N-acetylcysteine treatment Source: Eur Respir J 2005; 26: Suppl. 49, 83s Year: 2005 Nasal high-Flow (NHF) improves ventilation in patients with interstitial lung disease (ILD) Source: International Congress 2019 – Hot topics in noninvasive ventilation Year: 2019 Treatment of combined pulmonary fibrosis and emphysema Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Pulmonary alveolar proteinosis Source: Respipedia Article Year: 2017 Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF Source: Annual Congress 2010 - Rare diffuse lung diseases Year: 2010 Indication of whole lung lavage in pulmonary alveolar proteinosis – Retrospective study Source: International Congress 2015 – IIPs: orphan Year: 2015 Rituximab therapy in autoimmune pulmonary alveolar proteinosis Source: Eur Respir J 2009; 33: 1503-1506 Year: 2009